75 results about "Lipoprotein lipase" patented technology

The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor, insulin, or a functional fragment thereof. Nucleic acids encoding a chimeric CNS targeting polypeptide are also provided. Further provided is a method of delivering a polypeptide to the CNS of an individual. The method consists of administering to the individual an effective amount of a chimeric CNS targeting polypeptide, said chimeric CNS targeting polypeptide comprising a BBB-receptor binding domain and a payload polypeptide domain. The method also can deliver a polypeptide to the lysosomes of CNS cells.

The invention discloses a serum creatinine detecting reagent, and belongs to the technical field of clinical in-vitro detection. According to the serum creatinine detecting reagent, gamma-Fe2O3 nano-particles are added into a reagent R1, so that the activity of peroxidase and the specificity to a substrate are enhanced, and the interferences of reducing substances, such as ascorbic acid, uric acid, glutathione and bilirubin, are reduced; meanwhile, the gamma-Fe2O3 nano-particles also serve as a catalyst of a reaction; the interference of endogenous creatine is effectively eliminated by the combination action of the gamma-Fe2O3 nano-particles and the peroxidase. In addition, the serum creatinine detecting reagent adopts N-ethyl-N-(2-hydroxy-3-sulfonated propyl)-3-methylaniline sodium salt (TOOS) as a chromogen, so that the reagent is more stable; the analysis sensitivity is high. The substances, such as lipase and lipoprotein lipase, are also added into the reagent R1, so that the influence of lipid turbidity can be removed effectively; therefore, the reagent of the invention has higher anti-jamming capability and stability.

The present invention provides a method for a simple and accurate measurement of triglycerides in low-density lipoprotein in a sample comprising performing the following steps sequentially:

(i) a step of generating free glycerol by allowing lipoprotein lipase to act on a sample, in an aqueous medium comprising the sample and a specific surfactant such as polyoxyethylene polyoxyalkylene polycyclic phenyl ether; (ii) a step of removing free glycerol present in the reaction solution of the above step (i); (iii) a step of generating free glycerol by allowing lipoprotein lipase to act on the reaction solution from which free glycerol has been removed in step (ii), in the presence of a specific surfactant such as polyoxyethylene polyoxyalkylene alkyl ether; and (iv) a step of measuring free glycerol generated in step (iii),

and a kit used for the method.

There is provided a method for a selective assay of component, particularly cholesterol, in very low-density lipoprotein (VLDL) which is one of serum lipoproteins.

In the assay, an enzymatic reaction of lipoprotein lipase (LPL) or cholesterol esterase (CE) which well reacts with high-density lipoprotein (HDL) and VLDL is carried out at least in the presence of calixarene or a salt thereof. It is also carried out in the presence of one or more substance(s) selected from albumin and basic amino acids in addition to calixarene or a salt thereof.

The invention discloses a detection reagent for triglyceride and test paper for the triglyceride. The detection reagent comprises 18-25KU/L lipoprotein lipase, 20-30KU/L glycerol kinase, 3-5KU/L glycerine triphosphate oxidase, 7.5-9.0KU/L horse radish peroxidase, 3-5KU/L ascorbic acid oxidase, 0.20-0.35g/L 4-amino-antipyrineand 0.2-0.30g/L color material. The detection reagent contains multiple specific enzymes for particular proportioning, so that the targets that detection is fast and relatively accurate are achieved. The test paper comprises a reaction base layer, a reaction layer, a blood filtering layer and a hydrophillic layer, and a siphon system is formed by superposing the reaction base layer, the reaction layer, the blood filtering layer and the hydrophilic layer, so that fast detection and relatively accurate detection are further ensured.

A method of producing a phytomedicinal therapeutic for the prevention and control of a disease selected from the group consisting of obesity, cardiovascular disease, and diabetes, and conditions related thereto is provided which comprises extracting peanut shells with a solvent, removing a substantial portion of the solvent to produce a concentrated extract. Phytomedicinal compositions are provided that comprise an effective amount of at least one coumarin compound or one coumarin derivative derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL). Phytomedicinal compositions are provided that comprise at least an effective amount of coumarin derivatives (6,7-dihydroxycoumarin-esculetin, and esculetin-like compounds). A method for the prevention and/or treatment of treatment of a condition selected from the group consisting of obesity, cardiovascular disease, and diabetes, is provided which comprises administering a composition comprising an effective amount of at least one coumarin derivative, including 6,7-dihydroxycoumarin (esculetin), derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL).

The invention relates to a kit and a method for determining triglyceride. The kit comprises a reagent group 1 and a reagent group 2, wherein the reagent group 1 comprises magnesium salts, triphosadenine, glycerokinase, glycerol lipase oxidase, peroxidase and chromogen; the reagent group 2 comprises lipoprotein lipases and 4-amino-antipyrine, wherein the chromogen is N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (DAOS) or comprises DAOS. The kit and the method provided by the invention have the advantage that the interference caused by calcium dobesilate and/or etamsylate existing in the sample during the triglyceride detection can be reduced.

The invention discloses a method for measuring glucose oxidase without the interference of blood lipid. The method utilizes visible light to test a material according to the color change of reactions.According to the method, a reagent I comprises lipoprotein lipase, glycerol dehydrogenase, NAD+, Triton X-100, and mutarotase; and a reagent II comprises following effective components: glucose oxidase, peroxidase, and 4-amino antipyrine, and 2,4-dichlorophenol. The method comprises the following steps: placing serum and the reagent I in a water bath with a temperature of 37 DEG C for 3 to 5 minutes so as to convert triglyceride into dihydroxyl acetone under the action of lipoprotein lipase and glycerol dehydrogenase; and then adding the reagent II. Under the action of glucose oxidase and peroxidase, glucose, 4-amino antipyrine, and 2,4-dichlorophenol carry out condensation reactions to generate red quinone-imine. The first step is taken as blank by an instrument, and the glucose contentis calculated on the basis of quinone-imine generated in the step two.

Disclosed herein are peptides and peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein.

The invention provides a method for detecting a special growth and development law of muscles of Jingning chicken. The Jingning chicken are unique and peculiar local chicken of the Gansu province, are fresh and tender in texture and unique in flavor, and have good public praise, however, the Jingning chicken are endangered, and the prospect is grim. In the method for detecting the special growth and development law of the muscles of the Jingning chicken, chick embryos of the Jingning chicken are researched, and special meat quality trait controlling genes such as growth and development gap-associated proteins: CECR2 (cat eye syndrome chromosome region) and IGF-1 (insulinlike growth factor-1), fatty acid metabolism gap-associated proteins: Ex-FABP (fatty acid-binding protein) and LPL (lipoprotein lipase) and protein degradation gap-associated proteins: CAST and CAPN1 are selected. Protein expression distribution and change of expression level of proteins in posterior limb buds and body segments in a chick embryo development HH19-31 period are detected by using methods of immunohistochemistry and Western blotting and the like, and the Jingning chicken are compared to white feather broilers, yellow feather broilers and hyline brown chicken. By the method for detecting the special growth and development law of the muscles of the Jingning chicken, the relation of growth and development regulatory functional genes, growth performance and meat quality is discussed, and data are provided for establishing target genes of transgenic chicken. Moreover, the resource superiority can be widely developed and used, and new vitality is injected to development of local economy.

The invention relates to a Decapsulated artemia egg preparation method improving the hatching rate, and belongs to the technical field of artemia eggs. The decapsulated artemia egg preparation method improving the hatching rate includes the steps: taking haw as the raw material, juicing the haw, and performing dydration on artemia eggs by means of the haw juice with organic acidity and light salt brine; and by coordination of bile and phosphatidase C, decomposing the phosphatide and cholesterol in the eggshells of the artemia eggs, and by coordination of Candida rugosa bacterium and the lipoprotein lipase and active substance secreted from the Candida rugosa bacterium, and papain, decapsulating the artemia eggs, wherein the egg envelopes of the decapsulated eggs have high resistance to papain and lipoprotein lipase so that the reaction can be terminated even no special inhibitor is used and the decapsulated artemia eggs can be obtained. Through the decapsulated artemia egg preparation method improving the hatching rate, the hatching rate of the obtained decapsulated artemia eggs is greatly improved when the decapsulated artemia eggs are hatched, and achieves 93-96%. Moreover, the decapsulated artemia egg preparation method improving the hatching rate is stable in the decapsulating effect and is low in the operating difficulty.

The present invention relates to a method for conveniently quantitating TGs contained in various lipoproteins. A method for quantitating trigyceride (TG) in a particular lipoprotein which comprises eliminating free glycerol from a sample containing free glycerol and TG in the particular lipoprotein, then allowing the resulting sample to react with lipoprotein lipase and an enzyme system which generates hydrogen peroxide from free glycerol, and quantitating the generated hydrogen peroxide, is provided.

The invention discloses a cyclophorase determination method for triglyceride in serum, and belongs to a method for measuring materials by measuring color change generated by reactions. A technical solution lies in that a reagent I contains effective components of glycerol kinase, 3-phosphoglycerol dehydrogenase, phosphoglycerol oxidase, peroxidase, adenosine triphosphate, NADH, 4-aminoantipyrine and 2,4-dichlorophen; and a reagent II only contains an effective component of lipoprotein lipase. Free glycerol in the serum is subjected to circular reactions with adenosine triphosphate, NADH, 4-aminoantipyrine and 2,4-dichlorophen in the reagent I under catalysis of glycerol kinase, 3-phosphoglycerol dehydrogenase, phosphoglycerol oxidase and peroxidase to generate quinoneimine; and after the reagent II is added, triglyceride is hydrolyzed to generate glycerol, and then the circular reaction is carried out. The content of triglyceride is calculated by an instrument based on quinoneimine generated by reactions in the reagent II, by using quinoneimine generated by reactions in the reagent I as a blank.

The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.

The invention discloses a method for testing triglyceride in serum by using glycerol dehydrogenase, belonging to a method for testing a material through color change caused by a test reaction result by utilizing visible light. The technical scheme is as follows: a reagent I simultaneously contains glycerol dehydrogenase and NAD (Nicotinamide Adenine Dinucleotide)+, and a reagent II contains the effective component of lipoprotein lipase. The method comprises the steps of firstly, subjecting the serum and the reagent I to warm bath at the temperature of 37 DEG C for 3-5min; subjecting free glycerol in the serum and the reagent I to reaction to generate NADH (Nicotinamide Adenine Dinucleotide Hydrogen); adding the reagent II, and then, carrying out warm bath at the temperature of 37 DEG C for 4-7min; hydrolyzing the triglyceride to generate glycerol, and subjecting the glycerol to reaction to generate NADH; detecting on the position with the wavelength of 340nm by using an instrument; with the NADH generated by the reaction of the reagent I as a blank, calculating the content of the triglyceride according to the NADH generated by the reaction of the reagent II. When used for detecting, the method is not affected by endogenous glycerol; the method for testing the triglyceride is same as other enzyme methods in use and range, few in tool enzyme, little in hybrid enzyme interference, low in reagent cost, economic, convenient, feasible and higher in accuracy.

Provided are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia/FCS/LPLD, in a patient. Such methods, compounds, and compositions increase HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in the patient, and are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease, metabolic disorder, and associated symptoms.

The present invention provides an isolated DNA molecule that codes for a cell-surface binding protein in human monocytes and macrophages. In addition, an amino acid sequence derived from the nucleotide sequence is provided. The newly-identified cell-surface binding protein described herein is instrumental in the apoB-mediated cellular uptake of plasma chylomicrons and remnants and hypertriglyceridemic tryglyceride-rich lipoproteins in an ApoE- and lipoprotein lipase- and heparin sulfate proteoglycan-independent pathway. The present invention also provides evidence that the ligand for the receptor is within the N-terminal region of apoB-48 or B-100 at or near the lipoprotein lipase binding domain and not in a heparin binding domain.

Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders, including cardiovascular disease, diabetes and hypertension in mammals including domestic pets and humans. Apolipoprotein C-II or its active fractions can be used as a diet supplement in the form of fortification to a natural product such as milk, cereal, beverage; as a nutritional supplement; or as a therapeutic agent in conventional forms of administration.